Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 15, 2013, Pages 6109-6114

  Lin, De Chen ^a,b   Xu, Liang ^b   Ding, Ling Wen ^b   Sharma, Arjun ^b   Liu, Li Zhen ^b   Yang, Henry ^b   Tan, Patrick ^a   Vadgama, Jay ^c   Karlan, Beth Y ^d   Lester, Jenny ^d   Urban, Nicole ^e   Schummer, Michèl ^e   Doan, Ngan ^a   Said, Jonathan W ^a   Sun, Hongmao ^f   Walsh, Martin ^f   Thomas, Craig J ^f   Patel, Paresma ^g   Yin, Dong ^h   Chan, Daniel ⁱ   Phillip Koeffler, H ^a,b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e USA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g SAIC FREDERICK INC   (United States)

^h SUN YAT SEN UNIVERSITY   (China)

ⁱ NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; ENDOMETRIUM; EPITHELIUM CELL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE DELETION; GENE EXPRESSION; GENE LOSS; GENE PRODUCT; GENE REPRESSION; GENOMICS; GROWTH RETARDATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; NEOPLASM; OVARY; PRIORITY JOURNAL; SOLID TUMOR; STAINING; STOMACH; TUMOR GENE; UPREGULATION;

APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84876062367     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218206110     Document Type: Article

References (30)

1. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58(3):488-520.
2. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
3. Ke H, Wang H (2007) Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 7(4):391-403.
4. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 109(3):366-398.
5. Marko D, Pahlke G, Merz KH, Eisenbrand G (2000) Cyclic 3', 5'-nucleotide phosphodiesterases: Potential targets for anticancer therapy. Chem Res Toxicol 13(10):944-948.
6. Goldhoff P, et al. (2008) Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res 14(23):7717-7725.
7. Murata K, et al. (2000) Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility. Clin Exp Metastasis 18(7):599-604.
8. Kim DH, Lerner A (1998) Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 92(7):2484-2494.
9. Ogawa R, Streiff MB, Bugayenko A, Kato GJ (2002) Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 99 (9):3390-3397.
10. Koeffler HP, Golde DW (1980) Humoral modulation of human acute myelogenous leukemia cell growth in vitro. Cancer Res 40(6):1858-1862.
11. Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315.
12. Rahrmann EP, et al. (2009) Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 69(10):4388-4397.
13. Pullamsetti SS, et al. (2012) Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene 32(9):1121-1134.
14. Beroukhim R, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463(7283):899-905.
15. Zambon AC, Wilderman A, Ho A, Insel PA (2011) Increased expression of the proapoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells. J Biol Chem 286(38):33260-33267.
16. Garraway LA, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047):117-122.
17. Yi X, et al. (2011) MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther 19(2):362-371.
18. Carreira S, et al. (2005) Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433(7027):764-769.
19. Talantov D, et al. (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11(20):7234-7242.
20. Eskandarpour M, Huang F, Reeves KA, Clark E, Hansson J (2009) Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer 124(1):16-26.
21. Aspiotis R, et al. (2010) The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett 20(18):5502-5505.
22. Baillie G, MacKenzie SJ, Houslay MD (2001) Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 60(5):1100-1111.
23. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131(4):811-819.
24. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD (2000) ERK2 mitogenactivated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 275(22):16609-16617.
25. Jin SL, Swinnen JV, Conti M (1992) Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. J Biol Chem 267(26):18929-18939.
26. Kovala T, Sanwal BD, Ball EH (1997) Recombinant expression of a type IV, cAMP-specific phosphodiesterase: Characterization and structure-function studies of deletion mutants. Biochemistry 36(10):2968-2976.
27. Lim J, Pahlke G, Conti M (1999) Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain. J Biol Chem 274(28):19677-19685.
28. Bang YJ, et al. (1992) Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Natl Acad Sci USA 89(8):3556-3560.
29. Bang YJ, et al. (1994) Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 91(12):5330-5334.
30. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404.